Table 1

Major trials of blood pressure lowering treatment in diabetes

See box for explanation of trial acronyms.
Key trials containing large numbers of subjects with diabetes

  • ALLHAT: chlorthalidone, amlodipine, lisinopril, 33357 subjects, 12063 with diabetes

  • HOT: felodipine, 18790 subjects, 1501 with diabetes

  • LIFE: losartan, atenolol, 9193 subjects, 1195 with diabetes and left ventricular hypertrophy

  • SHEP: 4736 subjects, 583 with diabetes and systolic hypertension

  • Syst-Eur: 4695 subjects, 492 with diabetes and systolic hypertension

Major trials containing only subjects with diabetes

  • IRMA2: irbesartan, 590 subjects with diabetes and microalbuminuria

  • IDNT: irbesartan, 1715 subjects with diabetes and nephropathy

  • RENAAL: losartan, amlodipine, 1513 subjects with diabetes and nephropathy

  • UKPDS/HDS: atenolol, captopril, 1148 subjects with hypertension and newly diagnosed diabetes